Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
复制标题
DOI：
10.1111/joim.12854
复制
发表时间：
2019-04-01
影响因子：
11.1
通讯作者：
Nagler, A.
中科院分区：
文献类型：
--
作者：
Canaani, J.;Beohou, E.;Nagler, A.
背景。近年来，接受同种异体干细胞移植（allo-SCT）的急性髓系白血病（AML）患者的预后已显着改善。 目标。评估过去二十年来移植的 AML 患者的逐步改善。方法。该分析中包括的患者是在首次缓解时接受 HLA 匹配的同胞供体 (MSD) 或 HLA 匹配的无关供体 (MUD) 的同种异体 SCT 的成年 AML 患者。根据移植年份（1993-2002、2003-2007 和 2008-2012）对三个队列之间的患者结局进行评估。结果。该分析总共包括 20187 名患者，其中 1993 年至 2002 年期间有 4763 名患者进行了移植，2003 年和 2007 年有 5835 名患者进行了移植，2008 年和 2012 年有 9589 名患者进行了移植。在多变量分析中，与 1993-2002 年移植的患者相比，最近接受移植的患者的无白血病生存率 (LFS) 显着提高[风险比（HR）=0.84，置信区间（CI）95%，0.77-0.92； P=0.003]，这一益处还延伸至总生存期的改善（OS；HR=0.8，CI 95%，0.73-0.89；P
Background. Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years.Objectives. To assess the incremental improvement of transplanted AML patients in the last two decades.Methods. Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993-2002, 2003-2007 and 2008-2012).Results. The analysis comprised a total of 20187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993-2002 [Hazard ratio (HR)=0.84, confidence interval (CI) 95%, 0.77-0.92; P=0.003], a benefit which also extended to improved overall survival (OS; HR=0.8, CI 95%, 0.73-0.89; P